Department of Medicine, School of Medicine, University of California, Los Angeles, California, USA.
J Pharmacol Exp Ther. 2011 Nov;339(2):464-73. doi: 10.1124/jpet.111.184788. Epub 2011 Aug 16.
Luminal nutrient chemosensing during meal ingestion is mediated by intestinal endocrine cells, which regulate secretion and motility via the release of gut hormones. We have reported that luminal coperfusion of L-Glu and IMP, common condiments providing the umami or proteinaceous taste, synergistically increases duodenal bicarbonate secretion (DBS) possibly via taste receptor heterodimers, taste receptor type 1, member 1 (T1R1)/R3. We hypothesized that glucose-dependent insulinotropic peptide (GIP) or glucagon-like peptide (GLP) is released by duodenal perfusion with L-Glu/IMP. We measured DBS with pH and CO(2) electrodes through a perfused rat duodenal loop in vivo. GIP, exendin (Ex)-4 (GLP-1 receptor agonist), or GLP-2 was intravenously infused (0.01-1 nmol/kg/h). l-Glu (10 mM) and IMP (0.1 mM) were luminally perfused with or without bolus intravenous injection (3 or 30 nmol/kg) of the receptor antagonists Pro(3)GIP, Ex-3(9-39), or GLP-2(3-33). GIP or GLP-2 infusion dose-dependently increased DBS, whereas Ex-4 infusion gradually decreased DBS. Luminal perfusion of l-Glu/IMP increased DBS, with no effect of Pro(3)GIP or Ex-3(9-39), whereas GLP-2(3-33) inhibited L-Glu/IMP-induced DBS. Vasoactive intestinal peptide (VIP)(6-28) intravenously or N(G)-nitro-L-arginine methyl ester coperfusion inhibited the effect of L-Glu/IMP. Perfusion of L-Glu/IMP increased portal venous concentrations of GLP-2, followed by a delayed increase of GLP-1, with no effect on GIP release. GLP-1/2 and T1R1/R3 were expressed in duodenal endocrine-like cells. These results suggest that luminal L-Glu/IMP-induced DBS is mediated via GLP-2 release and receptor activation followed by VIP and nitric oxide release. Because GLP-1 is insulinotropic and GLP-2 is intestinotrophic, umami receptor activation may have additional benefits in glucose metabolism and duodenal mucosal protection and regeneration.
在进食过程中,肠内分泌细胞介导腔内营养化学感觉,通过释放肠道激素来调节分泌和运动。我们已经报道,共同提供鲜味或蛋白质味的腔肠内共灌注 L-Glu 和 IMP(肌苷酸单磷酸)通过味觉受体异二聚体、味觉受体 1 型成员 1(T1R1)/R3 协同增加十二指肠碳酸氢盐分泌(DBS)。我们假设十二指肠灌注 L-Glu/IMP 会释放葡萄糖依赖性胰岛素释放肽(GIP)或胰高血糖素样肽(GLP)。我们通过体内灌注大鼠十二指肠环测量 pH 和 CO2 电极的 DBS。静脉内输注 GIP、Exendin(Ex)-4(GLP-1 受体激动剂)或 GLP-2(0.01-1 nmol/kg/h)。用或不用受体拮抗剂 Pro(3)GIP、Ex-3(9-39)或 GLP-2(3-33)的静脉内推注(3 或 30 nmol/kg)腔内灌注 10 mM L-Glu 和 0.1 mM IMP。GIP 或 GLP-2 输注剂量依赖性地增加 DBS,而 Ex-4 输注逐渐降低 DBS。L-Glu/IMP 的腔内灌注增加 DBS,而 Pro(3)GIP 或 Ex-3(9-39)无作用,而 GLP-2(3-33)抑制 L-Glu/IMP 诱导的 DBS。静脉内给予血管活性肠肽(VIP)(6-28)或 N(G)-硝基-L-精氨酸甲酯共灌注抑制 L-Glu/IMP 的作用。L-Glu/IMP 灌注增加门脉静脉 GLP-2 浓度,随后 GLP-1 延迟增加,对 GIP 释放无影响。GLP-1/2 和 T1R1/R3 在十二指肠内分泌样细胞中表达。这些结果表明,腔内 L-Glu/IMP 诱导的 DBS 通过 GLP-2 释放和受体激活介导,随后是 VIP 和一氧化氮释放。由于 GLP-1 具有胰岛素样作用,GLP-2 具有肠营养作用,鲜味受体激活可能对葡萄糖代谢和十二指肠黏膜保护和再生具有额外益处。